What is the first diagnostic criterion for Familial Mediterranean Fever (FMF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The first diagnostic criteria for Familial Mediterranean Fever (FMF) were the Tel Hashomer criteria, developed in 1997, which remain the most widely used and accepted criteria for diagnosis, as supported by the study published in 1997 1.

Diagnostic Criteria

The Tel Hashomer criteria are divided into major and minor criteria. Major criteria include:

  • Recurrent febrile episodes with peritonitis, pleuritis, or synovitis
  • Amyloidosis of AA type without predisposing disease
  • Favorable response to colchicine treatment Minor criteria include:
  • Recurrent febrile episodes
  • Erysipelas-like erythema
  • FMF in a first-degree relative A definite diagnosis requires two major criteria or one major and two minor criteria, while a probable diagnosis requires one major and one minor criterion.

Clinical Presentation and Genetic Testing

These criteria were developed before genetic testing became widely available and rely primarily on clinical presentation, making them useful in clinical practice, especially in regions where genetic testing is not readily accessible, as noted in the study published in 2025 2.

Importance of Early Diagnosis

The diagnosis of FMF is important to establish early, as treatment with colchicine (typically 0.5-2 mg daily) can prevent recurrent attacks and the development of amyloidosis, which is the most serious complication of untreated FMF, as highlighted in the study published in 2020 3.

Treatment Options

For colchicine-resistant patients, IL-1 antagonists like anakinra and canakinumab show promise, although their long-term benefits require further investigation, as discussed in the study published in 2022 4.

Key Points

  • The Tel Hashomer criteria are the first and most widely used diagnostic criteria for FMF
  • Early diagnosis and treatment with colchicine can prevent recurrent attacks and amyloidosis
  • IL-1 antagonists are a treatment option for colchicine-resistant patients
  • Genetic testing can support diagnosis, but clinical presentation remains a key factor, as noted in the study published in 2015 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.